Edition:
United States

TherapeuticsMD Inc (TXMD.A)

TXMD.A on American Stock Exchange

4.89USD
4:00pm EDT
Change (% chg)

$-0.02 (-0.41%)
Prev Close
$4.91
Open
$4.95
Day's High
$5.08
Day's Low
$4.88
Volume
400,129
Avg. Vol
255,441
52-wk High
$9.28
52-wk Low
$4.39

Latest Key Developments (Source: Significant Developments)

TherapeuticsMD provides additional information on TX-004HR regulatory update
Wednesday, 19 Apr 2017 06:45am EDT 

April 19 (Reuters) - TherapeuticsMD Inc ::TherapeuticsMD provides additional information on TX-004HR regulatory update.TherapeuticsMD - expects FDA will finalize an action on NDA for TX-004HR on or before originally scheduled PDUFA target action date of May 7, 2017.At this time, company is not aware of nature of deficiencies in NDA identified by FDA.  Full Article

Therapeuticsmd provides TX-004HR regulatory update
Monday, 10 Apr 2017 08:00am EDT 

Therapeuticsmd Inc : Therapeuticsmd provides tx-004hr regulatory update . Therapeuticsmd Inc - on April 7, received a letter from fda . Therapeuticsmd-FDA says as part of review of tx-004hr nda, has identified deficiencies preclude discussion of labeling, postmarketing requirements/at this time . Therapeuticsmd inc - letter states that notification does not reflect a final decision on information under review . Therapeuticsmd Inc - letter does not specify deficiencies identified by FDA and at this time company is not aware of nature of deficiencies .Therapeuticsmd Inc - intends to work with fda to understand nature of deficiencies and resolve them as quickly as possible.  Full Article

Therapeuticsmd reports Q4 loss per share $0.12
Thursday, 23 Feb 2017 06:45am EST 

TherapeuticsMD Inc : TherapeuticsMD announces fourth quarter and full-year 2016 financial results . Q4 loss per share $0.12 . Q4 revenue $4.5 million versus $5.6 million . Q4 revenue view $5.9 million -- Thomson Reuters I/B/E/S . Q4 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S .TherapeuticsMD - pipeline of 2 late-stage product candidates advancing towards commercialization,launch of tx-004hr expected in Q4 pending regulatory approval.  Full Article

Franklin Resources reports 5.7 pct passive stake in TherapeuticsMD as of Dec. 31, 2016 - SEC filing
Tuesday, 7 Feb 2017 03:27pm EST 

:Franklin Resources, Inc reports 5.7 percent passive stake in TherapeuticsMD Inc as of Dec. 31, 2016 - SEC filing.  Full Article

TherapeuticsMD reports positive top-line results from pivotal phase 3 replenish trial in postmenopausal women with moderate to severe vasomotor symptoms (vms) treated with tx-001hr
Monday, 5 Dec 2016 04:05pm EST 

Therapeuticsmd Inc : TherapeuticsMD announces positive top-line results from pivotal phase 3 replenish trial in postmenopausal women with moderate to severe vasomotor symptoms (vms) treated with tx-001hr . To submit new drug application for tx-001hr to food and drug administration as early as q3 of 2017 . Very low reported incidence of adverse events of somnolence with tx-001hr .Additional efficacy and safety analyses of replenish trial data are ongoing.  Full Article

TherapeuticsMD announces Q3 2016 financial results
Thursday, 3 Nov 2016 04:05pm EDT 

TherapeuticsMD Inc : Qtrly revenues, net $ 5.5 million versus $ 5.2 million . TherapeuticsMD announces third quarter 2016 financial results . Q3 loss per share $0.13 .Q3 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.  Full Article

Therapeuticsmd reports Q2 loss per share $0.11
Thursday, 4 Aug 2016 04:05pm EDT 

Therapeuticsmd Inc : Therapeuticsmd announces second quarter 2016 financial results . Q2 loss per share $0.11 . Q2 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S .Topline phase 3 data for tx-001hr replenish trial on track for q4 of 2016.  Full Article

TherapeuticsMD, Inc announces pricing of common stock offering
Thursday, 7 Jan 2016 06:45am EST 

TherapeuticsMD, Inc:Announces pricing of $125 million common stock offering.Says public offering priced at $8.25 per share.  Full Article

TherapeuticsMD Announces $125 Million Offering of Common Stock
Tuesday, 5 Jan 2016 04:00pm EST 

TherapeuticsMD, Inc:Says launch of an underwritten public offering of $125 million of shares of its common stock.expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock.All of the shares in the offering are to be sold by TherapeuticsMD.The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Goldman, Sachs & Co. and Cowen and Company are acting as joint bookrunning managers for the offering.Stifel is acting as joint lead manager for the offering and Guggenheim Securities is acting as co-manager for the offering.intends to use a majority of the proceeds of the offering to fund commercialization activities for TX-004HR, its applicator-free vaginal estradiol softgel drug candidate, for other research, clinical trials, clinical formulation and development and for working capital and general corporate purposes.  Full Article

TherapeuticsMD announces positive top-line results from its phase 3 rejoice trial in postmenopausal women with vulvar and vaginal atrophy (vva) treated with 25 mcg, 10 mcg or 4 mcg of tx-004hr
Monday, 7 Dec 2015 04:10pm EST 

TherapeuticsMD:Says positive top-line results from its pivotal Phase 3 Rejoice Trial of TX-004HR, an investigational, applicator-free vaginal estradiol softgel.Says this is for treatment of moderate to severe dyspareunia (vaginal pain during sexual intercourse), a symptom of vulvar and vaginal atrophy (VVA) due to menopause.  Full Article

More From Around the Web